BioCentury
ARTICLE | Company News

FDA accepts Epanova NDA

September 19, 2013 1:29 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels greater than or equal to 500 mg/dL. The PDUFA date is May ...